Clinical Trial Update: Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Rituxan/BEAM versus Bexxar/BEAM in autologous stem cell transplantation for non-Hodgkin lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma B-cell
• Lymphoma Large-cell Immunoblastic
• Lymphoma Non-hodgkin

Drugs mentioned

• Bexxar/BEAM
• Rituxan/BEAM

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic | Phase 3 | Status: COMPLETED | Results posted: 2016-06-10